Join to access to all OVN content. Join for Free
The Ideal Roadmap for New MSLs
Medical Science Liaisons MSL career progression personal branding digital presence MSL training

The Ideal Roadmap for New MSLs


Share This Article


Summary

In this episode, Tom Caravela is joined by Sarah Snyder, MSL Recruiter at The Carolan Group and Co-Founder of MSL Mastery who discusses an ideal road map for new Medical Science Liaisons (MSLs). They walk through the 4 stages of what a new MSL experiences in the first full year. Building the foundation in months 1 to 3, Gaining momentum in months 3-6, becoming a trusted partner in months 6-12 and driving impact/delivering results at the 1 year mark and beyond. They also discuss tools and resources for enhancing MSL career progression and development. The episode explores personal branding, social media presence, and future trends in digital as well as AI for MSLs.

Key Points

  • Establishing a well-organized home office and staying updated in your therapeutic area is crucial for new MSLs to hit the ground running.
  • Building a strong foundation through structured training and certification is essential in the initial months to set the stage for becoming a trusted partner in the field.
  • Personal branding and maintaining a professional digital presence on platforms like LinkedIn are increasingly important for career advancement and networking as an MSL.

Click for Source
Medical Science Liaisons, MSL career progression, personal branding, digital presence, MSL training

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Promotability: How to Land Your Next Promotion
Partner Avatar Tom Caravela

Promotability: How to Land Your Next Promotion

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Explore OVN